Determining the prevalence and predictors of sleep disordered breathing in patients with chronic heart failure: rationale and design of the SCHLA-HF registry

BMC Cardiovascular Disorders

Study Protocol

Erland Erdmann¹  Olaf Oldenburg²  Michael Arzt³  Karl Wegscheider⁴  Helmut Teschler⁵  Andrea Graml⁶  Holger Woehrle⁷ 

[1] Clinic III for Internal Medicine, Heart Center University Hospital Cologne, Cologne, Germany;Department of Cardiology, Heart and Diabetes Center North Rhine-Westphalia, Bad Oeynhausen, Germany;Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany;Schlafmedizinisches Zentrum, Klinik und Poliklinik für Innere Medizin II, Universitätsklinikum Regensburg, Franz-Josef-Strauss-Allee 11, 93053, Regensburg, Germany;Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;Department of Pneumology, Respiratory and Sleep Medicine, Ruhrlandklinik, University Clinic Essen, Essen, Germany;ResMed Science Center, Martinsried, Germany;Sleep and Ventilation Center Blaubeuren, Respiratory Center Ulm, Ulm, Germany;ResMed Science Center, Martinsried, Germany;

关键词: Registry;    Prevalence;    Heart failure;    Sleep-disordered breathing;    Obstructive sleep apnea;    Central sleep apnea;    Cheyne-Stokes respiration;    Predictors;   

DOI  :  10.1186/1471-2261-14-46

 received in 2013-07-05, accepted in 2014-04-04,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundThe objective of the SCHLA-HF registry is to investigate the prevalence of sleep-disordered breathing (SDB) in patients with chronic heart failure with reduced left ventricular systolic function (HF-REF) and to determine predictors of SDB in such patients.MethodsCardiologists in private practices and in hospitals in Germany are asked to document patients with HF-REF into the prospective SCHLA-HF registry if they meet predefined inclusion and exclusion criteria. Screening was started in October 2007 and enrolment was completed at the end of May 2013. After enrolment in the registry, patients are screened for SDB. SDB screening is mainly undertaken using the validated 2-channel ApneaLink™ device (nasal flow and pulse oximetry; ResMed Ltd., Sydney, Australia). Patients with a significant number of apneas and hypopneas per hour recording time (AHI ≥15/h) and/or clinical symptoms suspicious of SDB will be referred to a cooperating sleep clinic for an attended in-lab polysomnography with certified scoring where the definite diagnosis and, if applicable, the differentiation between obstructive and central sleep apnea will be made. Suggested treatment will be documented.DiscussionRegistries play an important role in facilitating advances in the understanding and management of cardiovascular disease. The SCHLA-HF registry will provide consistent data on a large group of patients with HF-REF that will help to answer questions on the prevalence, risk factors, gender differences and stability of SDB in these patients by cross-sectional analyses. Further insight into the development of SDB will be gained by extension of the registry to include longitudinal data.

【 授权许可】

Unknown   
© Woehrle et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.